136 related articles for article (PubMed ID: 38745087)
1. A novel model incorporating quantitative contrast-enhanced ultrasound into PI-RADSv2-based nomogram detecting clinically significant prostate cancer.
Huang K; Luo L; Hong R; Zhao H; Li Y; Jiang Y; Feng Y; Fu Q; Zhou H; Li F
Sci Rep; 2024 May; 14(1):11083. PubMed ID: 38745087
[TBL] [Abstract][Full Text] [Related]
2. 3-T Multiparametric MRI Followed by In-Bore MR-Guided Biopsy for Detecting Clinically Significant Prostate Cancer After Prior Negative Transrectal Ultrasound-Guided Biopsy.
Hosseiny M; Shakeri S; Felker ER; Lu D; Sayre J; Ahuja P; Raman SS
AJR Am J Roentgenol; 2020 Sep; 215(3):660-666. PubMed ID: 32755166
[No Abstract] [Full Text] [Related]
3. Using decision curve analysis to benchmark performance of a magnetic resonance imaging-based deep learning model for prostate cancer risk assessment.
Deniffel D; Abraham N; Namdar K; Dong X; Salinas E; Milot L; Khalvati F; Haider MA
Eur Radiol; 2020 Dec; 30(12):6867-6876. PubMed ID: 32591889
[TBL] [Abstract][Full Text] [Related]
4. Dynamic contrast-enhanced imaging has limited added value over T2-weighted imaging and diffusion-weighted imaging when using PI-RADSv2 for diagnosis of clinically significant prostate cancer in patients with elevated PSA.
De Visschere P; Lumen N; Ost P; Decaestecker K; Pattyn E; Villeirs G
Clin Radiol; 2017 Jan; 72(1):23-32. PubMed ID: 27726850
[TBL] [Abstract][Full Text] [Related]
5. Role of PI-RADS Version 2 for Prediction of Upgrading in Biopsy-Proven Prostate Cancer With Gleason Score 6.
Song W; Bang SH; Jeon HG; Jeong BC; Seo SI; Jeon SS; Choi HY; Kim CK; Lee HM
Clin Genitourin Cancer; 2018 Aug; 16(4):281-287. PubMed ID: 29550198
[TBL] [Abstract][Full Text] [Related]
6. Is Prostate Imaging Reporting and Data System Version 2 Sufficiently Discovering Clinically Significant Prostate Cancer? Per-Lesion Radiology-Pathology Correlation Study.
Lee MS; Moon MH; Kim YA; Sung CK; Woo H; Jeong H; Son H
AJR Am J Roentgenol; 2018 Jul; 211(1):114-120. PubMed ID: 29702017
[TBL] [Abstract][Full Text] [Related]
7. PI-RADS Version 2: Detection of Clinically Significant Cancer in Patients With Biopsy Gleason Score 6 Prostate Cancer.
Seo JW; Shin SJ; Taik Oh Y; Jung DC; Cho NH; Choi YD; Park SY
AJR Am J Roentgenol; 2017 Jul; 209(1):W1-W9. PubMed ID: 28418690
[TBL] [Abstract][Full Text] [Related]
8. PI-RADS version 2: Preoperative role in the detection of normal-sized pelvic lymph node metastasis in prostate cancer.
Park SY; Shin SJ; Jung DC; Cho NH; Choi YD; Rha KH; Hong SJ; Oh YT
Eur J Radiol; 2017 Jun; 91():22-28. PubMed ID: 28629566
[TBL] [Abstract][Full Text] [Related]
9. The potential of a nomogram combined PI-RADS v2.1 and contrast-enhanced ultrasound (CEUS) to reduce unnecessary biopsies in prostate cancer diagnostics.
Liu Y; Wang S; Xiang LH; Xu G; Dong L; Sun Y; Ye B; Zhang Y; Xu H
Br J Radiol; 2022 Sep; 95(1138):20220209. PubMed ID: 35877385
[TBL] [Abstract][Full Text] [Related]
10. Multivariable stratification of PI-RADS version 2.1 categories for the risk of false-positive target biopsy: Impact on prostate biopsy decisions.
Girometti R; Giannarini G; De Martino M; Caregnato E; Cereser L; Soligo M; Rozze D; Pizzolitto S; Isola M; Zuiani C
Eur J Radiol; 2023 Aug; 165():110897. PubMed ID: 37300933
[TBL] [Abstract][Full Text] [Related]
11. Biparametric Magnetic Resonance Imaging-Derived Nomogram to Detect Clinically Significant Prostate Cancer by Targeted Biopsy for Index Lesion.
Kim MJ; Park SY
J Magn Reson Imaging; 2022 Apr; 55(4):1226-1233. PubMed ID: 34296803
[TBL] [Abstract][Full Text] [Related]
12. Preoperative PI-RADS Version 2 scores helps improve accuracy of clinical nomograms for predicting pelvic lymph node metastasis at radical prostatectomy.
Huang C; Song G; Wang H; Lin Z; Wang H; Ji G; Zhang S; Guo Y; Li J; Bao Z; Hong P; Du Y; Li P; He Q; He S; Gong Y; Wang X; Zhou L
Prostate Cancer Prostatic Dis; 2020 Mar; 23(1):116-126. PubMed ID: 31383954
[TBL] [Abstract][Full Text] [Related]
13. Comparison of multiple abbreviated multiparametric MRI-derived protocols for the detection of clinically significant prostate cancer.
Cereser L; Giannarini G; Bonato F; Pizzolitto S; Como G; Valotto C; Ficarra V; Dal Moro F; Zuiani C; Girometti R
Minerva Urol Nephrol; 2022 Feb; 74(1):29-37. PubMed ID: 33016030
[TBL] [Abstract][Full Text] [Related]
14. Diagnostic Performance of Prostate Imaging Reporting and Data System Version 2 for Detection of Prostate Cancer: A Systematic Review and Diagnostic Meta-analysis.
Woo S; Suh CH; Kim SY; Cho JY; Kim SH
Eur Urol; 2017 Aug; 72(2):177-188. PubMed ID: 28196723
[TBL] [Abstract][Full Text] [Related]
15. Comparison of different thresholds of PSA density for risk stratification of PI-RADSv2.1 categories on prostate MRI.
Girometti R; Giannarini G; Panebianco V; Maresca S; Cereser L; De Martino M; Pizzolitto S; Pecoraro M; Ficarra V; Zuiani C; Valotto C
Br J Radiol; 2022 Mar; 95(1131):20210886. PubMed ID: 34762506
[TBL] [Abstract][Full Text] [Related]
16. Validation of Prostate Imaging-Reporting and Data System Version 2: A Retrospective Analysis.
Nguyentat M; Ushinsky A; Miranda-Aguirre A; Uchio E; Lall C; Shirkhoda L; Lee T; Green C; Houshyar R
Curr Probl Diagn Radiol; 2018 Nov; 47(6):404-409. PubMed ID: 29126575
[TBL] [Abstract][Full Text] [Related]
17. The performance of PI-RADSv2 and quantitative apparent diffusion coefficient for predicting confirmatory prostate biopsy findings in patients considered for active surveillance of prostate cancer.
Nougaret S; Robertson N; Golia Pernicka J; Molinari N; Hötker AM; Ehdaie B; Sala E; Hricak H; Vargas HA
Abdom Radiol (NY); 2017 Jul; 42(7):1968-1974. PubMed ID: 28258355
[TBL] [Abstract][Full Text] [Related]
18. Prostate Imaging Reporting and Data System, Version 2, Assessment Categories and Pathologic Outcomes in Patients With Gleason Score 3 + 4 = 7 Prostate Cancer Diagnosed at Biopsy.
Lim CS; McInnes MDF; Flood TA; Breau RH; Morash C; Thornhill RE; Schieda N
AJR Am J Roentgenol; 2017 May; 208(5):1037-1044. PubMed ID: 28267359
[TBL] [Abstract][Full Text] [Related]
19. Development of a nomogram combining multiparametric magnetic resonance imaging and PSA-related parameters to enhance the detection of clinically significant cancer across different region.
Zhou Z; Liang Z; Zuo Y; Zhou Y; Yan W; Wu X; Ji Z; Li H; Hu M; Ma L
Prostate; 2022 Apr; 82(5):556-565. PubMed ID: 35098557
[TBL] [Abstract][Full Text] [Related]
20. Comparing Prostate Imaging-Reporting and Data System Version 2 (PI-RADSv2) Category 1 and 2 Groups: Clinical Implication of Negative Multiparametric Magnetic Resonance Imaging.
Kim JK; Lee HJ; Hwang SI; Choe G; Hong SK
Biomed Res Int; 2020; 2020():2819701. PubMed ID: 32337234
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
